📊 GCTK Key Takeaways
Is Glucotrack, Inc. (GCTK) a Good Investment?
Glucotrack exhibits critical financial distress with negative stockholders' equity of -$851K, virtually no revenue ($2.3K), and operating losses of -$4.2M. The company is burning approximately $4M annually with only ~$3.9M in cash reserves, indicating minimal runway before potential insolvency.
Glucotrack’s fundamentals remain extremely weak: revenue is effectively negligible, operating losses are very large, and free cash flow is deeply negative. While the company has low leverage and a sizable cash balance relative to its balance sheet, the current burn rate appears unsustainable without additional capital. The reported revenue growth is not high quality because it comes off an immaterial base and does not translate into improving profitability.
Glucotrack, Inc. Key Strengths (GCTK)
- Maintains $3.9M in cash reserves providing short-term liquidity buffer
- Capital expenditures are minimal at $96K, limiting further cash drain from investments
- Company maintains SEC compliance and reporting obligations
- No meaningful long-term debt, which limits balance-sheet leverage risk
- Cash and equivalents of $7.87M provide some near-term funding support
- Current and quick ratios above 1.5x indicate basic short-term liquidity is still intact
GCTK Stock Risks: Glucotrack, Inc. Investment Risks
- Negative stockholders' equity (-$851K) and liabilities exceeding assets indicate technical insolvency
- Operating cash burn of -$4.0M annually against minimal revenue creates less than 1-year cash runway
- Massive operating losses (-$4.2M) on revenue base of only $2.3K indicates no viable business model
- Revenue base is extremely small at $2.27K, indicating the business is not yet commercially established
- Operating loss of $12.60M and free cash flow of -$11.38M imply heavy ongoing cash burn
- Negative ROE, ROA, and net margin reflect severe structural unprofitability and likely future dilution risk
Key Metrics to Watch
- Revenue growth and path to breakeven profitability
- Cash burn rate and remaining months of runway
- Strategic alternatives and corporate restructuring announcements
- Quarterly revenue scale-up and whether sales become commercially meaningful
- Cash burn runway, especially operating cash flow versus cash balance
Glucotrack, Inc. (GCTK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
GCTK Profit Margin, ROE & Profitability Analysis
GCTK vs Healthcare Sector: How Glucotrack, Inc. Compares
How Glucotrack, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Glucotrack, Inc. Stock Overvalued? GCTK Valuation Analysis 2026
Based on fundamental analysis, Glucotrack, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Glucotrack, Inc. Balance Sheet: GCTK Debt, Cash & Liquidity
GCTK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Glucotrack, Inc.'s revenue has declined by 66% over the 5-year period, indicating business contraction. The most recent EPS of $4,106.00 reflects profitable operations.
GCTK Revenue Growth, EPS Growth & YoY Performance
GCTK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | $2.3K | -$509.0K | $0.00 |
| Q2 2020 | $97 | -$574.2K | $0.00 |
| Q1 2020 | $2.2K | -$714.5K | N/A |
| Q3 2019 | $4.2K | -$996.8K | $-0.01 |
| Q2 2019 | $15.3K | -$892.3K | $-0.01 |
| Q1 2019 | $25.6K | $1.0M | N/A |
| Q3 2018 | $20.9K | -$1.6M | $-0.31 |
| Q2 2018 | $8.7K | -$1.9M | $-0.33 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Glucotrack, Inc. Dividends, Buybacks & Capital Allocation
GCTK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Glucotrack, Inc. (CIK: 0001506983)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GCTK
What is the AI rating for GCTK?
Glucotrack, Inc. (GCTK) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GCTK's key strengths?
Claude: Maintains $3.9M in cash reserves providing short-term liquidity buffer. Capital expenditures are minimal at $96K, limiting further cash drain from investments. ChatGPT: No meaningful long-term debt, which limits balance-sheet leverage risk. Cash and equivalents of $7.87M provide some near-term funding support.
What are the risks of investing in GCTK?
Claude: Negative stockholders' equity (-$851K) and liabilities exceeding assets indicate technical insolvency. Operating cash burn of -$4.0M annually against minimal revenue creates less than 1-year cash runway. ChatGPT: Revenue base is extremely small at $2.27K, indicating the business is not yet commercially established. Operating loss of $12.60M and free cash flow of -$11.38M imply heavy ongoing cash burn.
What is GCTK's revenue and growth?
Glucotrack, Inc. reported revenue of $2.3K.
Does GCTK pay dividends?
Glucotrack, Inc. does not currently pay dividends.
Where can I find GCTK SEC filings?
Official SEC filings for Glucotrack, Inc. (CIK: 0001506983) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GCTK's EPS?
Glucotrack, Inc. has a diluted EPS of $2.65.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is GCTK's fundamental grade?
Based on our AI fundamental analysis in June 2026, Glucotrack, Inc. has a D grade with 94% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is GCTK stock overvalued or undervalued?
Valuation metrics for GCTK: ROE of N/A (sector avg: 15%), net margin of -190,841.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is GCTK's AI grade for 2026?
Our dual AI analysis gives Glucotrack, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GCTK's free cash flow?
Glucotrack, Inc.'s operating cash flow is $-4.0M, with capital expenditures of $96.0K. FCF margin is -182,474.7%.
How does GCTK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -190,841.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.85 (avg: 2).